Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Gynecology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 268 articles: HTML format

Single Articles

March 2021
1. WATTS EL, Perez-Cornago A, Knuppel A, Tsilidis KK, et al
   Prospective analyses of testosterone and SHBG with risk of 19 types of cancer in men and postmenopausal women in UK Biobank.
   Int J Cancer. 2021 Mar 15. doi: 10.1002/ijc.33555.
   PubMed     Abstract available
   
   
   
2. CHINULA L, Topazian HM, Mapanje C, Varela A, et al
   Uptake and safety of community-based 'screen-and-treat' with thermal ablation preventive therapy for cervical cancer prevention in rural Lilongwe, Malawi.
   Int J Cancer. 2021 Mar 9. doi: 10.1002/ijc.33549.
   PubMed     Abstract available
   
   
   February 2021
3. HALL MT, Smith MA, Simms KT, Barnabas R, et al
   Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
   Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33533.
   PubMed     Abstract available
   
   
   
4. YANG J, Sasamoto N, Babic A, Vitonis AF, et al
   Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses' Health Studies.
   Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33531.
   PubMed     Abstract available
   
   
   
5. HORTLUND M, van Mol T, Van de Pol F, Bogers JP, et al
   Human Papillomavirus Load and Genotype Analysis Improves the Prediction of Invasive Cervical Cancer.
   Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33519.
   PubMed     Abstract available
   
   
   
6. ARTHUR RS, Dannenberg AJ, Rohan TE
   The association of prediagnostic circulating levels of cardiometabolic markers, testosterone and SHBG with risk of breast cancer among normal weight postmenopausal women in the UK Biobank.
   Int J Cancer. 2021 Feb 10. doi: 10.1002/ijc.33508.
   PubMed     Abstract available
   
   
   January 2021
7. BETHEA TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, et al
   First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
   Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493.
   PubMed     Abstract available
   
   
   
8. O'BRIEN KM, Tworoger SS, Harris HR, Trabert B, et al
   Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies.
   Int J Cancer. 2021 Jan 12. doi: 10.1002/ijc.33470.
   PubMed     Abstract available
   
   
   
9. WANG B, Yao J, Ma R, Liu D, et al
   The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.
   Int J Cancer. 2021 Jan 5. doi: 10.1002/ijc.33460.
   PubMed     Abstract available
   
   
   December 2020
10. PARRA SG, Lopez-Orellana LM, Molina Duque AR, Carns JL, et al
    Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer.
    Int J Cancer. 2020 Dec 24. doi: 10.1002/ijc.33454.
    PubMed     Abstract available
    
    
    
11. LU W, He F, Lin Z, Liu S, et al
    Dysbiosis of the endometrial microbiota and its association with inflammatory cytokines in endometrial cancer.
    Int J Cancer. 2020 Dec 7. doi: 10.1002/ijc.33428.
    PubMed     Abstract available
    
    
    November 2020
12. LU Z, Zhu M, Marley JL, Bi K, et al
    The combined action of Mo-MDSCs and MAIT cells promotes the progression of cervical cancer.
    Int J Cancer. 2020 Nov 27. doi: 10.1002/ijc.33411.
    PubMed     Abstract available
    
    
    
13. AN Y, Yang Q
    Tumor-associated macrophage targeted therapeutics in ovarian cancer.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33408.
    PubMed     Abstract available
    
    
    
14. SINGH K, Gillett S, Ireson J, Hills A, et al
    M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first line treatment of high-risk Gestational Trophoblastic Neoplasia.
    Int J Cancer. 2020 Nov 19. doi: 10.1002/ijc.33403.
    PubMed     Abstract available
    
    
    
15. KESSOUS R, Wissing MD, Laskov I, Abitbol J, et al
    Multiple lines of chemotherapy for patients with high-grade ovarian cancer - predictors for response and effect on survival.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33395.
    PubMed     Abstract available
    
    
    
16. BIZZARRI N, Anchora LP, Cattani P, De Vincenzo R, et al
    Peritoneal Hpv-Dna Test In Cervical Cancer (Pioneer Study): A Proof Of Concept.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33380.
    PubMed     Abstract available
    
    
    October 2020
17. TIAN X, Ge D, Zhang F, Zhang B, et al
    Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33362.
    PubMed     Abstract available
    
    
    
18. JORDAN SJ, Na R, Weiderpass E, Adami HO, et al
    Pregnancy Outcomes and Risk of Endometrial Cancer: A Pooled Analysis of Individual Participant Data in the Epidemiology of Endometrial Cancer Consortium.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33360.
    PubMed     Abstract available
    
    
    
19. YANG C, Zhang L, Love-Gregory L, Sun L, et al
    Identification of Novel ALK Rearrangements in Gynecologic Clear Cell Carcinoma.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33330.
    PubMed     Abstract available
    
    
    
20. MAJIDI A, Na R, Jordan SJ, De Fazio A, et al
    Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33333.
    PubMed     Abstract available
    
    
    September 2020
21. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    PubMed     Abstract available
    
    
    August 2020
22. TODISCO E, Gigli F, Mantiero M, Sammassimo S, et al
    Clinical presentation, diagnosis and management of Therapy-Related Hematological Disorders in Women with Epithelial Ovarian Cancer treated with Chemotherapy and Poly-ADP-Ribose Polymerase Inhibitors (PARP-i): a single Center experience.
    Int J Cancer. 2020 Aug 28. doi: 10.1002/ijc.33269.
    PubMed     Abstract available
    
    
    
23. LOOPIK DL, Ebisch RM, IntHout J, Melchers WJ, et al
    The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.
    Int J Cancer. 2020;147:897-900.
    PubMed     Abstract available
    
    
    
24. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available
    
    
    July 2020
25. GUSTAFSON LW, Booth BB, Kahlert J, Ortoft G, et al
    Trends in hysterectomy-corrected uterine cancer mortality rates during 2002-2015: mortality of non-endometrioid cancer on the rise?
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33219.
    PubMed     Abstract available
    
    
    
26. LOUVANTO K, Eriksson T, Gray P, Apter D, et al
    Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.
    Int J Cancer. 2020;147:440-447.
    PubMed     Abstract available
    
    
    
27. KHO PF, Amant F, Annibali D, Ashton K, et al
    Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer.
    Int J Cancer. 2020 Jul 13. doi: 10.1002/ijc.33206.
    PubMed     Abstract available
    
    
    
28. ARBYN M, Gultekin M, Morice P, Nieminen P, et al
    The European response to the WHO call to eliminate cervical cancer as a public health problem.
    Int J Cancer. 2020 Jul 7. doi: 10.1002/ijc.33189.
    PubMed     Abstract available
    
    
    
29. PANOUTSOPOULOU K, Avgeris M, Magkou P, Mavridis K, et al
    miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33182.
    PubMed     Abstract available
    
    
    
30. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available
    
    
    June 2020
31. TOTA JE, Isidean SD, Franco EL
    Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33178.
    PubMed     Abstract available
    
    
    
32. WANG T, Bradshaw PT, Moorman PG, Nyante SJ, et al
    Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island Breast Cancer Study Project.
    Int J Cancer. 2020 Jun 25. doi: 10.1002/ijc.33174.
    PubMed     Abstract available
    
    
    
33. RAMACHANDRAN D, Schurmann P, Mao Q, Wang Y, et al
    Association of genomic variants at the Human Leukocyte Antigen locus with cervical cancer risk, HPV status, and gene expression.
    Int J Cancer. 2020 Jun 24. doi: 10.1002/ijc.33171.
    PubMed     Abstract available
    
    
    
34. GRAY P, Kann H, Pimenoff VN, Adhikari I, et al
    Long-term follow-up of human papillomavirus (HPV) type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage.
    Int J Cancer. 2020 Jun 23. doi: 10.1002/ijc.33169.
    PubMed     Abstract available
    
    
    
35. HANSEN JM, Nagle CM, Ibiebele TI, Grant PT, et al
    A healthy lifestyle and survival among women with ovarian cancer.
    Int J Cancer. 2020 Jun 16. doi: 10.1002/ijc.33155.
    PubMed     Abstract available
    
    
    
36. XIAO Q, James P, Breheny P, Jia P, et al
    Outdoor light at night and postmenopausal breast cancer risk in the NIH-AARP diet and health study.
    Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33016.
    PubMed     Abstract available
    
    
    May 2020
37. SENGAYI-MUCHENGETI M, Joko-Fru WY, Miranda-Filho A, Egue M, et al
    Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index (HDI): A population-based registry study.
    Int J Cancer. 2020 May 25. doi: 10.1002/ijc.33120.
    PubMed     Abstract available
    
    
    
38. LI Y, Hendryx MS, Xun P, He K, et al
    Physical activity and risk of bladder cancer among postmenopausal women.
    Int J Cancer. 2020 May 10. doi: 10.1002/ijc.33042.
    PubMed     Abstract available
    
    
    
39. LI X, Ding L, Song L, Gao W, et al
    Effects of exposure to polycyclic aromatic hydrocarbons combined with high-risk human papillomavirus infection on cervical intraepithelial neoplasia: A population study in Shanxi Province, China.
    Int J Cancer. 2020;146:2406-2412.
    PubMed     Abstract available
    
    
    April 2020
40. OMIYALE W, Allen NE, Sweetland S
    Body size, body composition and endometrial cancer risk among postmenopausal women in UK Biobank.
    Int J Cancer. 2020 Apr 27. doi: 10.1002/ijc.33023.
    PubMed     Abstract available
    
    
    
41. JIANG YT, Gong TT, Zhang JY, Li XQ, et al
    Infertility and ovarian cancer risk: evidence from nine prospective cohort studies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33012.
    PubMed     Abstract available
    
    
    
42. TIN ST, Reeves GK, Key TJ
    Body size and composition, physical activity and sedentary time in relation to endogenous hormones in pre- and post-menopausal women: findings from the UK Biobank.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33010.
    PubMed     Abstract available
    
    
    
43. JUNG M, Gao J, Cheung L, Bongers A, et al
    ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Int J Cancer. 2020 Apr 10. doi: 10.1002/ijc.33005.
    PubMed     Abstract available
    
    
    
44. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    PubMed     Abstract available
    
    
    
45. YANG H, Ye S, Goswami S, Li T, et al
    Highly immunosuppressive HLADR(hi) regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma.
    Int J Cancer. 2020;146:1993-2006.
    PubMed     Abstract available
    
    
    March 2020
46. GONG Y, Yang J, Wang Y, Xue L, et al
    Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites.
    Int J Cancer. 2020 Mar 24. doi: 10.1002/ijc.32990.
    PubMed     Abstract available
    
    
    
47. SINGH A, Gupta S, Badarukhiya JA, Sachan M, et al
    "Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer".
    Int J Cancer. 2020 Mar 19. doi: 10.1002/ijc.32984.
    PubMed     Abstract available
    
    
    
48. DASHTI SG, Viallon V, Simpson JA, Karahalios A, et al
    Explaining the link between adiposity and colorectal cancer risk in men and postmenopausal women in the UK Biobank: a sequential causal mediation analysis.
    Int J Cancer. 2020 Mar 17. doi: 10.1002/ijc.32980.
    PubMed     Abstract available
    
    
    
49. ESSERS PBM, van der Heijden M, Vossen D, de Roest RH, et al
    Ovarian cancer derived copy number alterations signatures are prognostic in chemoradiotherapy treated head and neck squamous cell carcinoma.
    Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32962.
    PubMed     Abstract available
    
    
    
50. KATO M, Onoyama I, Yoshida S, Cui L, et al
    Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
    Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32965.
    PubMed     Abstract available
    
    
    
51. PILLERON S, Cabasag CJ, Ferlay J, Bray F, et al
    Cervical cancer burden in Latin America and the Caribbean: Where are we?
    Int J Cancer. 2020 Mar 9. doi: 10.1002/ijc.32956.
    PubMed     Abstract available
    
    
    
52. HAMMER A, Demarco M, Campos N, Befano B, et al
    Study of the Risks of CIN3+ detection following multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32950.
    PubMed     Abstract available
    
    
    February 2020
53. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    PubMed     Abstract available
    
    
    
54. BENVENUTO G, Todeschini P, Paracchini L, Calura E, et al
    Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    Int J Cancer. 2020 Feb 25. doi: 10.1002/ijc.32935.
    PubMed     Abstract available
    
    
    
55. JOHN EM, Phipps AI, Hines LM, Koo J, et al
    Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and race/ethnicity: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2020 Feb 16. doi: 10.1002/ijc.32923.
    PubMed     Abstract available
    
    
    
56. KOTSOPOULOS J, Narod SA
    Prophylactic salpingectomy for the prevention of ovarian cancer; who should we target?
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32916.
    PubMed     Abstract available
    
    
    
57. VENETIANER R, Clarke MA, van der Marel J, Tota J, et al
    Identification of HPV Genotypes Causing Cervical Pre-Cancer using Tissue-Based Genotyping.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32919.
    PubMed     Abstract available
    
    
    
58. REIJNEN C, Kusters-Vandevelde HVN, Ligtenberg MJL, Bulten J, et al
    Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907.
    PubMed     Abstract available
    
    
    
59. HECK JE, Lee PC, Wu CK, Tsai HY, et al
    Gestational risk factors and childhood cancers: a cohort study in Taiwan.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32905.
    PubMed     Abstract available
    
    
    
60. LIPPENS L, Van Bockstal M, De Jaeghere EA, Tummers P, et al
    Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32893.
    PubMed     Abstract available
    
    
    
61. FORTNER RT, Husing A, Dossus L, Tjonneland A, et al
    Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32901.
    PubMed     Abstract available
    
    
    
62. MELIN J, Madanat-Harjuoja L, Hirvonen E, Seppa K, et al
    Use of fertility drugs in early-onset female cancer survivors-A Finnish register-based study on 8,929 survivors.
    Int J Cancer. 2020;146:829-838.
    PubMed     Abstract available
    
    
    
63. CLEVELAND AA, Gargano JW, Park IU, Griffin MR, et al
    Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Int J Cancer. 2020;146:810-818.
    PubMed     Abstract available
    
    
    January 2020
64. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    PubMed     Abstract available
    
    
    
65. MAYO-DE-LAS-CASAS C, Velasco A, Sanchez D, Martinez-Bueno A, et al
    Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: a proof-of-concept study.
    Int J Cancer. 2020 Jan 17. doi: 10.1002/ijc.32872.
    PubMed     Abstract available
    
    
    
66. AMITAY EL, Carr PR, Jansen L, Alwers E, et al
    Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways.
    Int J Cancer. 2020 Jan 14. doi: 10.1002/ijc.32868.
    PubMed     Abstract available
    
    
    
67. HANNIBAL CG, Frederiksen K, Vang R, Kurman RJ, et al
    Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide-based study.
    Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864.
    PubMed     Abstract available
    
    
    
68. YOSHIHARA M, Kajiyama H, Yokoi A, Sugiyama M, et al
    Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32854.
    PubMed     Abstract available
    
    
    December 2019
69. GABY S, Eva E, Andreas W, Wilhelm O, et al
    Reducing Overtreatment Associated with Overdiagnosis in Cervical Cancer Screening - A Model-based Benefit-Harm Analysis for Austria.
    Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32849.
    PubMed     Abstract available
    
    
    
70. KANN H, Hortlund M, Eklund C, Dillner J, et al
    Human Papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Int J Cancer. 2019 Dec 23. doi: 10.1002/ijc.32848.
    PubMed     Abstract available
    
    
    
71. RAMRAJ SK, Elayapillai SP, Pelikan RC, Zhao YD, et al
    Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32830.
    PubMed     Abstract available
    
    
    
72. LANDY R, Sasieni PD, Mathews C, Wiggins CL, et al
    Impact of screening on cervical cancer incidence. A population-based case-control study in the United States.
    Int J Cancer. 2019 Dec 13. doi: 10.1002/ijc.32826.
    PubMed     Abstract available
    
    
    
73. WOLF D, Fiegl H, Zeimet AG, Wieser V, et al
    High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
    Int J Cancer. 2019 Dec 4. doi: 10.1002/ijc.32818.
    PubMed     Abstract available
    
    
    
74. ELFSTROM KM, Sundstrom K, Andersson S, Bzhalava Z, et al
    Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.
    Int J Cancer. 2019;145:3033-3039.
    PubMed     Abstract available
    
    
    November 2019
75. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed     Abstract available
    
    
    
76. COSPER PF, McNair C, Gonzalez I, Wong N, et al
    Decreased Local Immune Response and Retained HPV Gene Expression during Chemoradiotherapy are Associated with Treatment Resistance and Death from Cervical Cancer.
    Int J Cancer. 2019 Nov 15. doi: 10.1002/ijc.32793.
    PubMed     Abstract available
    
    
    
77. YANG Y, Meng YL, Duan SM, Zhan SB, et al
    REBACIN(R) as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection.
    Int J Cancer. 2019;145:2712-2719.
    PubMed     Abstract available
    
    
    
78. ORUMAA M, Leinonen MK, Campbell S, Moller B, et al
    Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
    Int J Cancer. 2019;145:2629-2638.
    PubMed     Abstract available
    
    
    
79. MYERS AP, Konstantinopoulos PA, Barry WT, Luo W, et al
    Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32783.
    PubMed     Abstract available
    
    
    
80. WANG T, Townsend MK, Simmons V, Terry KL, et al
    Pre- and Post- Diagnosis Smoking and Survival Following Diagnosis with Ovarian Cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32773.
    PubMed     Abstract available
    
    
    
81. SOKOLENKO AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, et al
    Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776.
    PubMed     Abstract available
    
    
    October 2019
82. KRATZER TB, Weinstein SJ, Albanes D, Mondul AM, et al
    Vitamin D Binding Protein and Risk of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Int J Cancer. 2019 Oct 29. doi: 10.1002/ijc.32758.
    PubMed     Abstract available
    
    
    
83. SAND FL, Kjaer SK, Frederiksen K, Dehlendorff C, et al
    Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Int J Cancer. 2019 Oct 24. doi: 10.1002/ijc.32752.
    PubMed     Abstract available
    
    
    
84. FOKOM DOMGUE J, Futuh B, Ngalla C, Kakute P, et al
    Feasibility of a Community-based Cervical Cancer Screening with 'Test and Treat' strategy using self-sample for an HPV Test: Experience from rural Cameroon, Africa.
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32746.
    PubMed     Abstract available
    
    
    
85. FELIX AS, McLaughlin EM, Caan BJ, Cohn DE, et al
    Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32740.
    PubMed     Abstract available
    
    
    
86. LEE YJ, Kim D, Shim JE, Bae SJ, et al
    Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32729.
    PubMed     Abstract available
    
    
    
87. BRAUN JA, Herrmann AL, Blase JI, Frensemeier K, et al
    Effects of the Antifungal Agent Ciclopirox in HPV-Positive Cancer Cells: Repression of Viral E6/E7 Oncogene Expression and Induction of Senescence and Apoptosis.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32709.
    PubMed     Abstract available
    
    
    
88. SIMIN J, Rulla MT, Callens S, Engstrand L, et al
    Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32706.
    PubMed     Abstract available
    
    
    
89. ZORZI M, Del Mistro A, Giorgi Rossi P, Laurino L, et al
    Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow up.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32695.
    PubMed     Abstract available
    
    
    
90. QIU JJ, Lin XJ, Tang XY, Zheng TT, et al
    Long Noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32692.
    PubMed     Abstract available
    
    
    
91. CASTLE PE, Burk RD, Massad LS, Eltoum IE, et al
    Epidemiological Evidence that Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32693.
    PubMed     Abstract available
    
    
    September 2019
92. SADRI NAHAND J, Moghoofei M, Salmaninejad A, Bahmanpour Z, et al
    Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.
    Int J Cancer. 2019 Sep 30. doi: 10.1002/ijc.32688.
    PubMed     Abstract available
    
    
    
93. REIJNEN C, van der Putten LJM, Bulten J, Snijders MPLM, et al
    Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: a prospective multicentre cohort study.
    Int J Cancer. 2019 Sep 15. doi: 10.1002/ijc.32686.
    PubMed     Abstract available
    
    
    
94. LINK T, Passek S, Wimberger P, Frank K, et al
    Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32676.
    PubMed     Abstract available
    
    
    
95. LYU T, Jiang Y, Jia N, Che X, et al
    SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32673.
    PubMed     Abstract available
    
    
    
96. STOLER MH, Baker E, Boyle S, Aslam S, et al
    Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology - retrospective insights from ATHENA.
    Int J Cancer. 2019 Sep 6. doi: 10.1002/ijc.32669.
    PubMed     Abstract available
    
    
    
97. KONG Y, Wang Z, Huang M, Zhou Z, et al
    CUL7 promotes cancer cell survival through promoting Caspase-8 ubiquitination.
    Int J Cancer. 2019;145:1371-1381.
    PubMed     Abstract available
    
    
    
98. YI T, Feng Y, Sundaram R, Tie Y, et al
    Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Int J Cancer. 2019;145:1209-1220.
    PubMed     Abstract available
    
    
    August 2019
99. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
    Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
    PubMed     Abstract available
    
    
    
100. RICE MS, Poole EM, Willett WC, Tworoger SS, et al
     Adult Dietary Fat Intake and Ovarian Cancer Risk.
     Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32635.
     PubMed     Abstract available
     
     
     
101. VINK FJ, Meijer CJLM, Clifford GM, Poljak M, et al
     FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
     Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614.
     PubMed     Abstract available
     
     
     
102. RAY-COQUARD I, Cibula D, Mirza MR, Reuss A, et al
     Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
     Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32606.
     PubMed     Abstract available
     
     
     
103. RIGHOLT CH, Bozat-Emre S, Mahmud SM
     Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
     Int J Cancer. 2019;145:671-677.
     PubMed     Abstract available
     
     
     July 2019
104. TAWE L, MacDuffie E, Narasimhamurthy M, Wang Q, et al
     Human Papillomavirus (HPV) Genotypes in Women with Invasive Cervical Cancer with and without Human Immunodeficiency Virus (HIV) Infection in Botswana.
     Int J Cancer. 2019 Jul 20. doi: 10.1002/ijc.32581.
     PubMed     Abstract available
     
     
     
105. RAAB M, Kobayashi NF, Becker S, Kurunci-Csacsko E, et al
     Boosting the apoptotic response of high grade serous ovarian cancers with CCNE1-amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
     Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32559.
     PubMed     Abstract available
     
     
     
106. ZHU Q, Zhang J, Chen Y, Hu Q, et al
     Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.
     Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.
     PubMed     Abstract available
     
     
     
107. BERTOLI HK, Rasmussen CL, Sand FL, Albieri V, et al
     Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina.
     Int J Cancer. 2019;145:78-86.
     PubMed     Abstract available
     
     
     June 2019
108. COLDMAN AJ, van Niekerk D, Krajden M, Smith LW, et al
     Disease Detection at the 48 Month Exit Round of the HPV FOCAL Cervical Cancer Screening Trial in Women Per-Protocol Eligible for Routine Screening.
     Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32524.
     PubMed     Abstract available
     
     
     
109. ROHNER E, Butikofer L, Schmidlin K, Sengayi M, et al
     Cervical cancer risk in women living with HIV across four continents: A multicohort study.
     Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32260.
     PubMed     Abstract available
     
     
     
110. GRUNDY A, Ho V, Abrahamowicz M, Parent ME, et al
     Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: a case-control study.
     Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32513.
     PubMed     Abstract available
     
     
     
111. COSTAS L, Frias-Gomez J, Guardiola M, Benavente Y, et al
     New perspectives on screening and early detection of endometrial cancer.
     Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32514.
     PubMed     Abstract available
     
     
     
112. DASHTI SG, Simpson JA, Karahalios A, Viallon V, et al
     Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: quantification of the mediating effects of fasting insulin and free estradiol.
     Int J Cancer. 2019 Jun 12. doi: 10.1002/ijc.32504.
     PubMed     Abstract available
     
     
     
113. ZENG X, Baba T, Hamanishi J, Matsumura N, et al
     Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
     Int J Cancer. 2019 Jun 10. doi: 10.1002/ijc.32501.
     PubMed     Abstract available
     
     
     
114. TRABERT B, Troisi R, Grotmol T, Ekbom A, et al
     Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: a Nordic population-based case-control study.
     Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32494.
     PubMed     Abstract available
     
     
     
115. MPUNGA T, Umulisa MC, Tenet V, Rugwizangoga B, et al
     Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
     Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32491.
     PubMed     Abstract available
     
     
     
116. WOESTENBERG PJ, Bogaards JA, King AJ, Leussink S, et al
     Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
     Int J Cancer. 2019;144:2718-2727.
     PubMed     Abstract available
     
     
     May 2019
117. MORI N, Sawada N, Iwasaki M, Yamaji T, et al
     Circulating sex hormone levels and colorectal cancer risk in Japanese postmenopausal women: The JPHC nested case-control study.
     Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32431.
     PubMed     Abstract available
     
     
     
118. WANG J, Elfstrom KM, Andrae B, Nordqvist Kleppe S, et al
     Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening programme.
     Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32416.
     PubMed     Abstract available
     
     
     
119. TIAN W, Bi R, Ren Y, He H, et al
     Screening for hereditary cancers in patients with endometrial cancer reveals a high frequency of germline mutations in cancer predisposition genes.
     Int J Cancer. 2019 May 4. doi: 10.1002/ijc.32389.
     PubMed     Abstract available
     
     
     
120. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
     Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
     Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
     PubMed     Abstract available
     
     
     
121. BAO C, Yang R, Pedersen NL, Xu W, et al
     Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
     Int J Cancer. 2019;144:2128-2134.
     PubMed     Abstract available
     
     
     April 2019
122. ASSI N, Rinaldi S, Viallon V, Dashti SG, et al
     Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC Cohort.
     Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32324.
     PubMed     Abstract available
     
     
     
123. CABASAG CJ, Arnold M, Butler J, Inoue M, et al
     The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
     Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32322.
     PubMed     Abstract available
     
     
     
124. AMARO-FILHO SM, Gradissimo A, Usyk M, Moreira FCB, et al
     HPV73 a non-vaccine type causes cervical cancer.
     Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32315.
     PubMed     Abstract available
     
     
     March 2019
125. NURMI A, Muranen TA, Pelttari LM, Kiiski JI, et al
     Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
     Int J Cancer. 2019 Mar 30. doi: 10.1002/ijc.32309.
     PubMed     Abstract available
     
     
     
126. TIAN J, Geng Y, Lv D, Li P, et al
     Using plasma cell free DNA to monitor the chemo-radiotherapy course of cervical cancer.
     Int J Cancer. 2019 Mar 28. doi: 10.1002/ijc.32295.
     PubMed     Abstract available
     
     
     
127. LI H, Zhang W, Niu C, Lin C, et al
     Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
     Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32293.
     PubMed     Abstract available
     
     
     
128. BALLABIO S, Craparotta I, Paracchini L, Mannarino L, et al
     Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number variation in 3p26.2 and 8q24.3.
     Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32288.
     PubMed     Abstract available
     
     
     
129. BONDE J, Bottari F, Parvu V, Pedersen H, et al
     BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND >/=CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT.
     Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32291.
     PubMed     Abstract available
     
     
     
130. LANDY R, Schiffman M, Sasieni PD, Cheung LC, et al
     Absolute risks of cervical precancer among women who fulfil exiting guidelines based on HPV and cytology cotesting.
     Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32268.
     PubMed     Abstract available
     
     
     February 2019
131. 
     Expression of Concern: "Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells" by Hua Yang, Lili He, Patricia Kruk, Santo V. Nicosia and Jin Q. Cheng.
     Int J Cancer. 2019 Feb 27. doi: 10.1002/ijc.32225.
     PubMed    
     
     
     
132. HE Y, Gu Z, Zhu Q, Chen M, et al
     CA125 over-release behavior following a 75-gram oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer.
     Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32237.
     PubMed     Abstract available
     
     
     
133. ARRIAGA ME, Vajdic CM, Canfell K, MacInnis RJ, et al
     The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: a pooled cohort study.
     Int J Cancer. 2019 Feb 25. doi: 10.1002/ijc.32231.
     PubMed     Abstract available
     
     
     
134. VAN LEEUWEN RW, Ostrbenk A, Poljak M, van der Zee AGJ, et al
     DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
     Int J Cancer. 2019;144:746-754.
     PubMed     Abstract available
     
     
     January 2019
135. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
     Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
     Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
     PubMed     Abstract available
     
     
     
136. LI F, Li H, Zhang L, Li W, et al
     X chromosome-linked long noncoding RNA lnc-XLEC1 regulates c-Myc-dependent cell growth by collaborating with MBP-1 in endometrial cancer.
     Int J Cancer. 2019 Jan 30. doi: 10.1002/ijc.32166.
     PubMed     Abstract available
     
     
     
137. RIOS P, Bailey HD, Poulalhon C, Valteau-Couanet D, et al
     Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies.
     Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32161.
     PubMed     Abstract available
     
     
     
138. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
     Fiber Intake and the Risk of Head and Neck Cancer in the prostate, lung, colorectal, and ovarian (PLCO) cohort.
     Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32162.
     PubMed     Abstract available
     
     
     
139. TRABERT B, Michels KA, Anderson GL, Brinton LA, et al
     Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.
     Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32157.
     PubMed     Abstract available
     
     
     
140. FERRERA A, Valladares W, Cabrera Y, de la Luz Hernandez M, et al
     Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer.
     Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32156.
     PubMed     Abstract available
     
     
     
141. CERVENKA I, Al Rahmoun M, Mahamat Saleh Y, Savoye I, et al
     Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
     Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32150.
     PubMed     Abstract available
     
     
     
142. PAN J, Kavanagh K, Cuschieri K, Pollock KG, et al
     Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease.
     Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32126.
     PubMed     Abstract available
     
     
     
143. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
     Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
     Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
     PubMed     Abstract available
     
     
     
144. LEEMAN A, Del Pino M, Marimon L, Torne A, et al
     Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
     Int J Cancer. 2019;144:160-168.
     PubMed     Abstract available
     
     
     December 2018
145. VAN HELLEMOND IEG, Vriens IJH, Peer PGM, Swinkels ACP, et al
     Efficacy of Anastrozole after Tamoxifen in Early Breast Cancer Patients with Chemotherapy-Induced Ovarian Function Failure.
     Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32093.
     PubMed     Abstract available
     
     
     
146. FORTNER RT, Poole EM, Wentzensen NA, Trabert B, et al
     Ovarian cancer risk factors by tumor aggressiveness: an analysis from the Ovarian Cancer Cohort Consortium.
     Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32075.
     PubMed     Abstract available
     
     
     
147. HAMERS FF, Assogba FAG, Rogel A
     Implementation and organization of cancer screening in France.
     Int J Cancer. 2018;143:3281.
     PubMed    
     
     
     
148. ANDREASSEN T, Hansen BT, Engesaeter B, Hashim D, et al
     Psychological Effect of Cervical Cancer Screening When Changing Primary Screening Method From Cytology to hrHPV testing.
     Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32067.
     PubMed     Abstract available
     
     
     
149. SULTANA F, Winch K, Saville M, Brotherton JM, et al
     Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?
     Int J Cancer. 2018 Dec 10. doi: 10.1002/ijc.32050.
     PubMed     Abstract available
     
     
     
150. RADER JS, Tsaih SW, Fullin D, Murray MW, et al
     Genetic variations in human papillomavirus and cervical cancer outcomes.
     Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32038.
     PubMed     Abstract available
     
     
     
151. HALEC G, Scott ME, Farhat S, Darragh TM, et al
     Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2.
     Int J Cancer. 2018;143:2884-2891.
     PubMed     Abstract available
     
     
     November 2018
152. KIM S, Wang M, Tyrer JP, Jensen A, et al
     A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
     Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
     PubMed     Abstract available
     
     
     
153. UTADA M, Chernyavskiy P, Lee WJ, Franceschi S, et al
     Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012.
     Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32014.
     PubMed     Abstract available
     
     
     
154. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
     Management of HPV-Positive Women in Cervical Screening Using Results from Two Consecutive Screening Rounds.
     Int J Cancer. 2018 Nov 22. doi: 10.1002/ijc.32004.
     PubMed     Abstract available
     
     
     
155. SCHUBERT S, van Luttikhuizen JL, Auber B, Schmidt G, et al
     The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.
     Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31992.
     PubMed     Abstract available
     
     
     
156. RATAJ O, Haedicke-Jarboui J, Stubenrauch F, Iftner T, et al
     Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy.
     Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31986.
     PubMed     Abstract available
     
     
     
157. COOK DA, Krajden M, Brentnall AR, Gondara L, et al
     Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
     Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31976.
     PubMed     Abstract available
     
     
     
158. ISIDEAN SD, Wang Y, Mayrand MH, Ratnam S, et al
     Assessing the Time Dependence of Prognostic Values of Cytology and Human Papillomavirus Testing in Cervical Cancer Screening.
     Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31970.
     PubMed     Abstract available
     
     
     
159. RAGLAN O, Kalliala I, Markozannes G, Cividini S, et al
     Risk Factors for Endometrial Cancer: An umbrella review of the literature.
     Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31961.
     PubMed     Abstract available
     
     
     
160. PIMENOFF VN, Tous S, Benavente Y, Alemany L, et al
     Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: results from a worldwide cross-sectional study.
     Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31964.
     PubMed     Abstract available
     
     
     October 2018
161. KAMINENI A, Tiro JA, Beaber EF, Silverberg MJ, et al
     Cervical Cancer Screening Research in the PROSPR I Consortium: Rationale, Methods, and Baseline Findings from a U.S. Cohort.
     Int J Cancer. 2018 Oct 24. doi: 10.1002/ijc.31940.
     PubMed     Abstract available
     
     
     
162. MACKINTOSH ML, Derbyshire AE, McVey RJ, Bolton J, et al
     The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk.
     Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31913.
     PubMed     Abstract available
     
     
     September 2018
163. ELANDS RJ, Offermans NS, Simons CC, Schouten LJ, et al
     Associations of adult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status.
     Int J Cancer. 2018 Sep 25. doi: 10.1002/ijc.31890.
     PubMed     Abstract available
     
     
     
164. SAND FL, Munk C, Frederiksen K, Junge J, et al
     Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
     Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31883.
     PubMed     Abstract available
     
     
     
165. LIU Z, Zhang S, Hou F, Zhang C, et al
     Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.
     Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31887.
     PubMed     Abstract available
     
     
     
166. TSANG SH, Peisch SF, Rowan B, Markt SC, et al
     Association between Trichomonas vaginalis and prostate cancer mortality.
     Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31885.
     PubMed     Abstract available
     
     
     
167. WANG Q, Song R, Zhao C, Liu H, et al
     HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1.
     Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31876.
     PubMed     Abstract available
     
     
     
168. MONDAL S, Roy D, Sarkar Bhattacharya S, Jin L, et al
     Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
     Int J Cancer. 2018 Sep 18. doi: 10.1002/ijc.31868.
     PubMed     Abstract available
     
     
     
169. KOMEMI O, Epstein Shochet G, Pomeranz M, Fishman A, et al
     Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
     Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31861.
     PubMed     Abstract available
     
     
     
170. SNOEK BC, Verlaat W, Babion I, Novianti PW, et al
     Genome-wide microRNA analysis of HPV-positive self-samples yields novel triage markers for early detection of cervical cancer.
     Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31855.
     PubMed     Abstract available
     
     
     
171. FALK RT, Manson JE, Barnabei VM, Anderson GL, et al
     Estrogen metabolism in menopausal hormone users in the Women's Health Initiative Observational Study: Does it differ between estrogen plus progestin and estrogen alone?
     Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31851.
     PubMed     Abstract available
     
     
     
172. LI J, Wen WX, Eklund M, Kvist A, et al
     Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
     Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
     PubMed     Abstract available
     
     
     
173. BAUSSANO I, Lazzarato F, Ronco G, Franceschi S, et al
     Impacts of human papillomavirus vaccination for different populations: A modeling study.
     Int J Cancer. 2018;143:1086-1092.
     PubMed     Abstract available
     
     
     August 2018
174. ZHANG C, Wang X, Anaya Y, Parodi L, et al
     Distinct Molecular Pathways in Ovarian Endometrioid Adenocarcinoma with Concurrent Endometriosis.
     Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31768.
     PubMed     Abstract available
     
     
     
175. OSTERMAN AL, Winer RL, Gottlieb GS, Sy MP, et al
     Female genital mutilation and non-invasive cervical abnormalities and invasive cervical cancer in Senegal, West Africa: A retrospective study.
     Int J Cancer. 2018 Aug 24. doi: 10.1002/ijc.31829.
     PubMed     Abstract available
     
     
     
176. JOSHI S, Muwonge R, Kulkarni V, Deodhar K, et al
     Incidence of cervical intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) with no evidence of disease at baseline: results of a prospective cohort study with up to 6.4 years of follow-up from India.
     Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31826.
     PubMed     Abstract available
     
     
     
177. CAMPOS NG, Tsu V, Jeronimo J, Regan C, et al
     Health impact of delayed implementation of cervical cancer screening programs in India: A modelling analysis.
     Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31823.
     PubMed     Abstract available
     
     
     
178. JIN C, Liu Z, Li Y, Bu H, et al
     PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.
     Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31800.
     PubMed     Abstract available
     
     
     
179. BUCCHI L, Baldacchini F, Mancini S, Ravaioli A, et al
     Estimating the impact of an organised screening programme on cervical cancer incidence: a 26-year study from northern Italy.
     Int J Cancer. 2018 Aug 18. doi: 10.1002/ijc.31806.
     PubMed     Abstract available
     
     
     
180. LU X, Li Y, Xia B, Bai Y, et al
     Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based non-targeted and targeted analyses.
     Int J Cancer. 2018 Aug 16. doi: 10.1002/ijc.31807.
     PubMed     Abstract available
     
     
     
181. KIVES Z, Juhasz K, Csakvari T, Agoston I, et al
     Cancer screening policy in Hungary.
     Int J Cancer. 2018;143:1003-1004.
     PubMed    
     
     
     
182. NEFF R, Rush CM, Smith B, Backes FJ, et al
     Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.
     Int J Cancer. 2018 Aug 9. doi: 10.1002/ijc.31784.
     PubMed     Abstract available
     
     
     
183. HE W, Hou M, Zhang H, Zeng C, et al
     Clinical significance of circulating tumor cells in predicting disease progression and chemotherapy resistance in patients with gestational choriocarcinoma.
     Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31742.
     PubMed     Abstract available
     
     
     
184. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
     Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
     Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
     PubMed     Abstract available
     
     
     
185. GOMIH A, Smith JS, North KE, Hudgens MG, et al
     DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions.
     Int J Cancer. 2018;143:552-560.
     PubMed     Abstract available
     
     
     July 2018
186. CHEN HJ, Huang RL, Liew PL, Su PH, et al
     GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
     Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31750.
     PubMed     Abstract available
     
     
     
187. AKINWUNMI B, Vitonis AF, Titus L, Terry KL, et al
     Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study.
     Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31758.
     PubMed     Abstract available
     
     
     
188. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
     Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
     Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
     PubMed     Abstract available
     
     
     
189. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
     Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
     Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
     PubMed    
     
     
     
190. BLUMENFELD Z
     Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
     Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
     PubMed    
     
     
     
191. SAAVALAINEN L, Lassus H, But A, Tiitinen A, et al
     A nationwide cohort study on the risk of non-gynaecological cancers in women with surgically verified endometriosis.
     Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31721.
     PubMed     Abstract available
     
     
     
192. AUSTRIA T, Marion C, Yu V, Widschwendter M, et al
     Mechanism of cytokinesis failure in ovarian cystadenomas with defective brca1 and p53 pathways.
     Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31659.
     PubMed     Abstract available
     
     
     
193. CERVENKA I, Mahamat-Saleh Y, Savoye I, Dartois L, et al
     Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study.
     Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31644.
     PubMed     Abstract available
     
     
     
194. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
     Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
     Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
     PubMed     Abstract available
     
     
     June 2018
195. GUSTAVSSON I, Aarnio R, Berggrund M, Hedlund-Lindberg J, et al
     Randomized study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel.
     Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31637.
     PubMed     Abstract available
     
     
     
196. REZHAKE R, Hu SY, Zhao S, Xu XQ, et al
     Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
     Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31633.
     PubMed     Abstract available
     
     
     
197. DYG SPERLING C, Verdoodt F, Kjaer Hansen M, Dehlendorff C, et al
     Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study.
     Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31625.
     PubMed     Abstract available
     
     
     
198. KO KP, Kim SJ, Huzarski T, Gronwald J, et al
     The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
     Int J Cancer. 2018;142:2263-2272.
     PubMed     Abstract available
     
     
     May 2018
199. OLORUNFEMI G, Ndlovu N, Masukume G, Chikandiwa A, et al
     Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).
     Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31610.
     PubMed     Abstract available
     
     
     
200. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
     Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
     Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
     PubMed     Abstract available
     
     
     
201. BIZZARO F, Falcetta F, D'Agostini E, Decio A, et al
     Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
     Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31596.
     PubMed     Abstract available
     
     
     
202. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
     Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.
     Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581.
     PubMed     Abstract available
     
     
     
203. HUANG RL, Chen HJ, Chen LY, Chao TK, et al
     Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
     Int J Cancer. 2018 May 7. doi: 10.1002/ijc.31580.
     PubMed     Abstract available
     
     
     April 2018
204. CHAN KK, Wong OG, Wong ES, Chan KK, et al
     Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
     Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31535.
     PubMed     Abstract available
     
     
     
205. DE STROOPER LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, et al
     Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
     Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31539.
     PubMed     Abstract available
     
     
     
206. CHAN KK, Wong OG, Wong ES, Chan KK, et al
     Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
     Int J Cancer. 2018 Apr 12. doi: 10.1002/ijc.31427.
     PubMed     Abstract available
     
     
     
207. AGOSTINI A, Brunetti M, Davidson B, Trope CG, et al
     Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
     Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31418.
     PubMed     Abstract available
     
     
     
208. CUBURU N, Khan S, Thompson CD, Kim R, et al
     Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins.
     Int J Cancer. 2018;142:1467-1479.
     PubMed     Abstract available
     
     
     March 2018
209. ANNUNZIATA C, Pezzuto F, Greggi S, Ionna F, et al
     Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
     Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31412.
     PubMed     Abstract available
     
     
     
210. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
     A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
     Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
     PubMed     Abstract available
     
     
     
211. PAPAEVANGELOU E, Almeida GS, Box C, deSouza NM, et al
     The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
     Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31392.
     PubMed     Abstract available
     
     
     
212. KELLEN E, Benoy I, Vanden Broeck D, Martens P, et al
     A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program.
     Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31391.
     PubMed     Abstract available
     
     
     
213. GUO W, Key TJ, Reeves GK
     Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
     Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
     PubMed     Abstract available
     
     
     
214. VINTERMYR OK, Andersland MS, Bjorge T, Skar R, et al
     Human papillomavirus type specific risk of progression and remission during long term follow-up of equivocal and low grade HPV-positive cervical smears.
     Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31390.
     PubMed     Abstract available
     
     
     
215. BROOKS JD, Sung JS, Pike MC, Orlow I, et al
     MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women.
     Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31370.
     PubMed     Abstract available
     
     
     
216. YU L, Jiang M, Qu P, Wu Z, et al
     Clinical Evaluation of Human Papillomavirus 16/18 Oncoprotein Test for Cervical Cancer Screening and HPV Positive Women Triage.
     Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31368.
     PubMed     Abstract available
     
     
     
217. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
     Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
     Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
     PubMed     Abstract available
     
     
     
218. LEHTINEN M, Soderlund-Strand A, Vanska S, Luostarinen T, et al
     Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
     Int J Cancer. 2018;142:949-958.
     PubMed     Abstract available
     
     
     February 2018
219. KABAT GC, Kim MY, Stefanick M, Ho GYF, et al
     Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women.
     Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31345.
     PubMed     Abstract available
     
     
     
220. KAAKS R, Fortner RT, Husing A, Barrdahl M, et al
     Tumor-associated auto-antibodies as early detection markers for ovarian cancer? A prospective evaluation.
     Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31335.
     PubMed     Abstract available
     
     
     
221. DEL MISTRO A, Adcock R, Carozzi F, Gillio-Tos A, et al
     HPV genotyping for the cross-sectional and longitudinal probability of developing CIN2.
     Int J Cancer. 2018 Feb 17. doi: 10.1002/ijc.31326.
     PubMed     Abstract available
     
     
     
222. LIEW PL, Huang RL, Weng YC, Fang CL, et al
     Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
     Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31324.
     PubMed     Abstract available
     
     
     
223. RIETBERGEN MM, van Bokhoven AAJD, Lissenberg-Witte BI, Heideman DAM, et al
     Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions.
     Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31315.
     PubMed     Abstract available
     
     
     
224. LECAVALIER-BARSOUM M, Chaudary N, Han K, Koritzinsky M, et al
     Targeting the CXCL12/CXCR4 Pathway and Myeloid Cells to Improve Radiation Treatment of Locally Advanced Cervical Cancer.
     Int J Cancer. 2018 Feb 8. doi: 10.1002/ijc.31297.
     PubMed     Abstract available
     
     
     
225. FALCONER H, Yin L, Altman D
     Association between tubal ligation and endometrial cancer risk: A Swedish population-based cohort study.
     Int J Cancer. 2018 Feb 1. doi: 10.1002/ijc.31287.
     PubMed     Abstract available
     
     
     January 2018
226. YANG X, Wang N, Chen J
     Subsequent primary malignancies after endometrial cancer diagnosed in American cancer registries.
     Int J Cancer. 2018 Jan 31. doi: 10.1002/ijc.31284.
     PubMed    
     
     
     
227. ZHENG J, Merchant AT, Wirth MD, Zhang J, et al
     Inflammatory potential of diet and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
     Int J Cancer. 2018 Jan 22. doi: 10.1002/ijc.31271.
     PubMed     Abstract available
     
     
     
228. LOKKEGAARD ECL, Morch LS
     Tibolone and risk of gynecological hormone sensitive cancer.
     Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31267.
     PubMed     Abstract available
     
     
     
229. DE KOK IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, et al
     Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
     Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31265.
     PubMed     Abstract available
     
     
     
230. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
     Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
     Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
     PubMed     Abstract available
     
     
     
231. CUSCHIERI K, Ronco G, Lorincz A, Smith L, et al
     Eurogin Roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programmes.
     Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31261.
     PubMed     Abstract available
     
     
     
232. BASU P, Ponti A, Anttila A, Ronco G, et al
     Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
     Int J Cancer. 2018;142:44-56.
     PubMed     Abstract available
     
     
     December 2017
233. LUOSTARINEN T, Apter D, Dillner J, Eriksson T, et al
     Vaccination protects against invasive HPV-associated cancers.
     Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31231.
     PubMed    
     
     
     
234. GULTEKIN M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, et al
     Initial results of population based cervical cancer screening program using hpv testing in one million turkish women.
     Int J Cancer. 2017 Dec 13. doi: 10.1002/ijc.31212.
     PubMed     Abstract available
     
     
     
235. KHAIRALLAH AS, Genestie C, Auguste A, Leary A, et al
     Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
     Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31200.
     PubMed    
     
     
     
236. SAND FL, Frederiksen K, Munk C, Jensen SM, et al
     Long-Term Risk of Cervical Cancer Following Conization of Cervical Intraepithelial Neoplasia Grade 3 - A Danish Nationwide Cohort Study.
     Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31202.
     PubMed     Abstract available
     
     
     
237. KANG YJ, Smith M, Barlow E, Coffey K, et al
     Vulvar cancer in high-income countries: Increasing burden of disease.
     Int J Cancer. 2017;141:2174-2186.
     PubMed     Abstract available
     
     
     
238. REIMER D, Boesch M, Wolf D, Marth C, et al
     Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.
     Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31186.
     PubMed     Abstract available
     
     
     November 2017
239. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
     Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
     Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
     PubMed     Abstract available
     
     
     
240. FORTNER RT, Schock H, Le Cornet C, Husing A, et al
     Ovarian Cancer Early Detection by Circulating CA125 in the context of Anti-CA125 Autoantibody Levels: Results from the EPIC cohort.
     Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31164.
     PubMed     Abstract available
     
     
     
241. KIM J, Field A, Schultz KAP, Hill DA, et al
     The prevalence of DICER1 pathogenic variation in population databases.
     Int J Cancer. 2017;141:2030-2036.
     PubMed     Abstract available
     
     
     
242. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
     Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
     Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
     PubMed     Abstract available
     
     
     
243. RASMUSSEN CL, Sand FL, Hoffmann Frederiksen M, Andersen KK, et al
     Does HPV status influence survival after vulvar cancer?
     Int J Cancer. 2017 Nov 1. doi: 10.1002/ijc.31139.
     PubMed     Abstract available
     
     
     October 2017
244. CUPPENS T, Moisse M, Depreeuw J, Annibali D, et al
     Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
     Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31129.
     PubMed     Abstract available
     
     
     
245. FELIX AS, Brasky TM, Cohn DE, Mutch DG, et al
     Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
     Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31127.
     PubMed     Abstract available
     
     
     
246. MATSUZAKI S, Serada S, Hiramatsu K, Nojima S, et al
     Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
     Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31124.
     PubMed     Abstract available
     
     
     
247. LANDY R, Windridge P, Gillman MS, Sasieni PD, et al
     What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
     Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31094.
     PubMed     Abstract available
     
     
     
248. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
     Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
     Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
     PubMed     Abstract available
     
     
     
249. PAN R, Zhu M, Yu C, Lv J, et al
     Cancer incidence and mortality: A cohort study in China, 2008-2013.
     Int J Cancer. 2017;141:1315-1323.
     PubMed     Abstract available
     
     
     September 2017
250. VIDART D'EGURBIDE BAGAZGOITIA , Bailey HD, Orsi L, Lacour B, et al
     Maternal residential pesticide use during pregnancy and risk of malignant childhood brain tumors: A pooled analysis of the ESCALE and ESTELLE studies (SFCE).
     Int J Cancer. 2017 Sep 26. doi: 10.1002/ijc.31073.
     PubMed     Abstract available
     
     
     
251. GAITSKELL K, Green J, Pirie K, Barnes I, et al
     Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study.
     Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31063.
     PubMed     Abstract available
     
     
     
252. RICE MS, Rist PM, Winter AC, Kurth T, et al
     Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
     Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31062.
     PubMed     Abstract available
     
     
     
253. JUNG S, Allen N, Arslan AA, Baglietto L, et al
     Anti-Mullerian Hormone and risk of ovarian cancer in nine cohorts.
     Int J Cancer. 2017 Sep 18. doi: 10.1002/ijc.31058.
     PubMed     Abstract available
     
     
     
254. QUIST AJL, Inoue-Choi M, Weyer PJ, Anderson KE, et al
     Ingested nitrate and nitrite, disinfection by-products, and pancreatic cancer risk in postmenopausal women.
     Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31055.
     PubMed     Abstract available
     
     
     
255. FABER MT, Sand FL, Albieri V, Norrild B, et al
     Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.
     Int J Cancer. 2017;141:1161-1169.
     PubMed     Abstract available
     
     
     
256. ZHANG Q, Dong L, Hu S, Feng R, et al
     Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
     Int J Cancer. 2017;141:1110-1119.
     PubMed     Abstract available
     
     
     August 2017
257. RAKISLOVA N, Clavero O, Alemany L, Saco A, et al
     "Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1594 cases".
     Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.31006.
     PubMed     Abstract available
     
     
     
258. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
     Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
     Int J Cancer. 2017;141:701-710.
     PubMed     Abstract available
     
     
     
259. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
     Three-year cancer incidence in Blantyre, Malawi (2008-2010).
     Int J Cancer. 2017;141:694-700.
     PubMed     Abstract available
     
     
     July 2017
260. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
     Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
     Int J Cancer. 2017;141:393-404.
     PubMed     Abstract available
     
     
     
261. GU F, Zhang H, Hyland PL, Berndt S, et al
     Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
     Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
     PubMed     Abstract available
     
     
     
262. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
     Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
     Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
     PubMed     Abstract available
     
     
     June 2017
263. MATSUMOTO K, Yaegashi N, Iwata T, Yamamoto K, et al
     Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
     Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30855.
     PubMed    
     
     
     May 2017
264. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
     Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
     Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.
     PubMed    
     
     
     
265. SHEN C, Liu Y, Shi S, Zhang R, et al
     Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
     Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
     PubMed     Abstract available
     
     
     April 2017
266. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
     Worldwide burden of cancer attributable to HPV by site, country and HPV type.
     Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
     PubMed     Abstract available
     
     
     January 2017
267. MANCINI S, Ravaioli A, Giuliani O, Vattiato R, et al
     Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors.
     Int J Cancer. 2017;140:247-248.
     PubMed    
     
     
     December 2016
268. BOGANI G, Chiappa V, Martinelli F, Raspagliesi F, et al
     Type-Specific HPV Infection Correlates with Risk of Recurrence of Vulvar Intraepithelial Neoplasia Usual Type.
     Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30585.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: